Clinical trials



KEK

#No.

Insel

#No.

Current Clinical Trials

 

 

Cohort trials

143/15

-

Congenital extrahepatic portosystemic shunts (Abernethy malformation): European Survey of current management strategies and clinical outcome.

923/16 - Pro-Euro DILI Registry - Creation of a Multicentre and Multidisciplinary European Registry of Prospective Drug-Induced Liver Injury Cases (Pro-Euro-DILI).

 

 

Liver Cancer

111/15

2961

LILLY (REACH 2) : I4T-MC-JVDE: Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib” (Lilly).

370/15

3034

Bristol-Myers Squibb Clinical Trial Agreement BMS CA209-459: A randomized, multi-center Phase Ill Study of Nivolumab versus Sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (CheckMate 459).

0347/18 1898 HCC Cohort: Cohort Study with patients suffering from hepatocellular carcinoma.
275/17 3534 Blueprint HCC: BLU-554-1101 A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with HCC.
1760/18 3805 Axl S: sAxl as Diagnostic Biomarker of Steatosis- and Hepatitis Virus-Induced Hepatocellular Carcinoma.
1585/18 3916 CEUS: Contrast-enhanced ultrasound for the assessment of focal liver lesions in patients with cirrhosis or other risk factors for a Hepatocellular Carcinoma (HCC).
0400/19 4053 MK3475-937: A Phase 3 Double-blinded, Twoarm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937).
2392/18 4003 Cosmic(Exelixis) (OASIS): XL184-312, a randomized, controlled phase 3 study of Cabozantinib (XL184) in combination with Atezolizumab versus Sorafenib in patients with advanced HCC who have not received previous systemic anticancer therapy.

 

 

Viral Hepatitis

922/16

-

HBV Cohort. Swiss Hepatitis B Cohort Study. SASL 37.

338/14

2755

Abbvie M14-423: A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II).

0727/18 3715 DAA  and Cancer: Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of intra- and extrahepatic Malignancies in Patients with Chronic Hepatitis C.
- - CMV T-Track.
   

Metabolic Liver Diseases

 324/15

3042

Intercept 747-303 NASH (REGENERATE): A phase 3, double-blind, randomized, long-term, placebo-controlled, multicenter study evaluating the safety and efficacy of obeticholic acid in subjects with nonalcoholic steatohepatitis NASH.

1003/16

3225

GENFIT: Resolve-it: Genfit GFT505 in NASH phase 3: A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of elafibranor in patients with non-alcoholic steatohepatitis NASH and Fibrosis (Emricasan).

0294/18 3662 Litmus - The European NAFLD Registry Liver Investigation: Testing Marker Utility in Steatohepatitis.
0609/19 4067 Litmus sub-study imaging: Litmus Sub-Study Imaging: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment and Validation of Imaging Modality Performance across the NAFLD Spectrum in a Prospectively Recruited Cohort.
0980/19 4102 NUT-3/NAS (Falk GmbH): Double-blind, randomised, placebo-controlled, phase IIb trial on the efficacy and safety of norursodeoxycholic acid tablets in patients with non-alcoholic steatohepatitis (NASH).
0898/17 3942 Aurora (Tobira) Allergan : A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (TOBIRA).

 

 

Cirrhosis

0548/17 3352 GS-US-384-1944 Cirrhosis on NASH: A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of Selonsertib in subjects with compensated cirrhosis due to nonalcoholic steatohepatitis, Stellar-4.
- - NABEL Cirhosis Data Bank (Canada and Bern).
198/15 2854

Prosper: Phase IV observational hepatic encephalopathy +/- rifaximin.

 

 

Vascular Liver Diseases

213/13

2492

Valdig Consortium for the promotion of the study of vacular liver diseases.

 

 

Autoimmune Liver Diseases

366/15 3004 Intercept 747-302 Cobalt: A Phase 3b, double-blind, randomized, placebo-controlled, multicenter study evaluating the effect of obeticholic acid on clinical outcomes in subjects with primary biliary cirrhosis.

1665/16

3272

SASL 38: Swiss Registry on Autoimmune Hepatitis.

1666/16

3253

SASL 39: Swiss Registry on Primary Biliary Cholangitis.

2236/16 3320 SASL 40: Swiss cohort on Primary Sclerosing Cholangitis SWISS PSC.
1508/18 - SASL 43: IgG4 Swiss Cohort. Swiss IgG4-Related Hepato-Biliary Disease Cohort Study.
1918/18 3952 NUC-5-PSC (Navitas) Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary slerosing cholangitis.
1968/17 3597 Novartis CVAY736B2201. A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (AMBER).

 

 

Others

1253/18 3720 The Constans Study: A multi-center, multinational survey of NAFLD-related hospital visits: prevalence, severity, patterns of clinical practive and health-care costs. (Consultations for steatohepatitis).

0604/19

4314

Investigation of liver involvement in patients with Alpha1-Antitrypsin Deficiency.

487/18 - Combination of non-invasive Tests in chronic liver disease to improve a stage-targeted risk stratification and outcome prediction.

 

 

Closed Studies

 

 

List